Screening method based on tsap 6 binding partners
OwnerRobert Amson, Adam Teleman +1inventors
InventorsRobert Amson, Adam Teleman, Brent Passer
Life of this patent
Estimating the term…
Abstract
The invention concerns methods for detecting, identifying and/or screening compounds in particular for use in treating cancers and certain neurodegenerative diseases related to dysfunction in tumour suppression regulation and/or apoptosis, in the biological chain of p53, said methods being based on interaction between TSAP6 and its binding partners identified in the present invention.
Claims14
A method for identifying a compound which inhibits the binding of TSAP6 to one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48, having the steps of:
- a) bringing said compound into contact with a system for determining, in vitro, the binding between TSAP6 and one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47 or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48;
- b) identifying the decrease in and/or the inhibition of the binding between TSAP6 and said protein defined in a).
A method for identifying a compound which makes it possible to increase tumor reversion and/or cell death (apoptosis), characterized in that it has the steps of:
- a) bringing compounds into contact with a system for determining, in vitro, the binding between TSAP6 and one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48;
- b) identifying the compounds which induce the decrease in and/or the inhibition of the binding between TSAP6 and said protein defined in a);
- c) bringing the compounds identified in step b) into contact in a system for measuring the phenomena of apoptosis and/or of tumor reversion;
- d) identifying the increase in tumor reversion and/or in cell death (apoptosis) in said model by comparison with a control model with which said compound has not been brought into contact.
A method for identifying a compound for decreasing and/or inhibiting tumor reversion and/or cell death (apoptosis), having the steps of:
- a) bringing compounds into contact with a system for determining, in vitro, the binding between TSAP6 and one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48;
- b) identifying the compounds which induce the decrease in and/or the inhibition of the binding between TSAP6 and said protein defined in a);
- c) bringing the compounds identified in step b) into contact in a system for measuring the phenomena of apoptosis and/or of tumor reversion;
- d) identifying the decrease in and/or the inhibition of tumor reversion and/or cell death (apoptosis) in said model by comparison with a control model with which said compound has not been brought into contact.
A method for identifying regions of TSAP6 which are involved in the binding with one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48, comprising the steps of:
- a) bringing peptides derived from the TSAP6 protein into contact in a system for determining, in vitro, the binding between TSAP6 and said protein chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48;
- b) identifying the peptides which lead to the decrease in the binding between TSAP6 and said protein chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID No 46 or 48, in said system.
A complex consisting of a TSAP6 protein and of one of the proteins chosen from SEQ ID No 1 to SEQ ID No 35 or SEQ ID No 44, 45 or 47, or encoded by a nucleic acid chosen from SEQ ID No 36 to SEQ ID No 43 or SEQ ID-No 46 or 48.
Dependencies are inferred from the claim text.